1

ADVANCED CHILD PSYCHOPHARMACOLOGY

REFERENCES

(Updated April 2017)

GENERAL REFERENCES:

Textbooks:

Connor DF, Meltzer BM (2006), Pediatric Psychopharmacology: Fast Facts. New York,

NY: W.W. Norton & Company

Elbe D, Bezchlibnyk-Butler KZ, Virani AS, Procyshyn RM eds. (2014), Clinical

Handbook of Psychotropic Drugs for Children and Adolescents. 3rd ed. Boston, MA:

Hogrefe Publishing

Findling RL ed (2013), Clinical Manual of Child and Adolescent Psychopharmacology.

2nd ed. Arlington, VA: American Psychiatric Publishing, Inc.

Klykylo W, Bowers R, Jackson J, Weston C (2013), Green’s Child & Adolescent Clinical

Psychopharmacology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins

Martin A, Scahill L, Kratochvil C eds. (2011), Pediatric Psychopharmacology:

Principles and Practice. 2nd ed. New York, NY: Oxford University Press

Martin A, Volkmar FR eds. (2007), Lewis's Child and Adolescent Psychiatry: A

Comprehensive Textbook. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins

Sadock BJ, Sadock VA, Ruiz P eds. (2017), Kaplan & Sadock’s Comprehensive

Textbook of Psychiatry. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins

Journals

Journal of the American Academy of Child and Adolescent Psychiatry

Note that JAACAP has published a wide range of practice parameters:

www.aacap.org/cs/root/member_information/practice_information/practice_parameter

s/practice_parameters

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Journal of Child and Adolescent Psychopharmacology

For Families and Teachers:

Dulcan MK, Ballard RR ed. (2015), Helping Parents and Teachers Understand

Medications for Behavioral and Emotional Problems: A Resource Book of Medication

Information Handouts. 4th ed. Arlington, VA: American Psychiatric Publishing, Inc.

Wilens TE, Hammerness PG (2016), Straight Talk about Psychiatric Medications for

Kids. 4th ed. New York: The Guilford Press.

= required reading = suggested reading 2

REFERENCES FOR SEMINARS:

Introductory Seminar: “Kids Aren’t Little Adults”

Credibility crisis in pediatric psychiatry (editorial, no authors given). Nat Neurosci 2008;

11:983.

Albert PR. Drugs for kids: good or bad? J Psychiatry Neurosci 2012; 37:293-5.

American Academy of Child & Adolescent Psychiatry. AACAP official action. Practice

parameters for the use of psychotropic medications in children and adolescents. J Am

Acad Child Adolesc Psychiatry 2009; 48:967-73.

Angell M. Drug companies & doctors: a story of corruption. The New York Review of

books, January 15, 2009.

Carlat D. Mind Over Meds. New York Times Magazine, April 19, 2010.

Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic

medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;

45:771-91.

Correll CU, Kratochvil CJ, March JS. Developments in pediatric

psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J

Clin Psychiatry 2011;72:655-70. (Read for second introductory seminar.)

Cowen PJ. Has psychopharmacology got a future? Br J Psychiatry 2011; 198:333-5.

Garcia G, Logan GE, Gonzalez-Heydrich J. Management of psychotropic medication

side effects in children and adolescents. Child Adolesc Psychiatric Clin N Am 2012;

21:713-38.

Ghaemi SN. Toward a Hippocratic psychopharmacology. Can J Psychiatry 2008;53:189-

96.

Olfson M, Druss BG, Marcus SC. Trends in mental health care among children and

adolescents. N Engl J Med 2015; 372:2029-38.

Pescosolido BA, Perry BL, Martin JK, McLeod JD, Jensen PS. Stigmatizing attitudes and

beliefs about treatment and psychiatric medications for children with mental illness.

Psychiatr Serv 2007; 58:613-8.

Pichini S, Papaseit E, Joya X, Vall O, Farre M, Garcia-Algar O, et al. Pharmacokinetics

and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit

2009; 31:283-318.

Rapoport JL. Pediatric psychopharmacology: too much or too little? World Psychiatry

2013; 12:118-23.

Smoller JW: The etiology and treatment of childhood. www.pfc.org.uk/node/595

1998. (Read for first introductory seminar.)

Stroeh O, Trivedi HK. Appropriate and judicious use of psychotropic medications in

youth. Child Adolesc Psychiatr Clin N Am 2012; 21:703-11.

= required reading = suggested reading 3

Vitiello B. Developmental aspects of pediatric psychopharmacology. In: Findling RL, ed.

Clinical Manual of Child and Adolescent Psychopharmacology. Arlington, VA:

American Psychiatric Publishing, Inc; 2008: 1-31.

Critical Appraisal – Fundamental Concepts

Greenhalgh, T., Howick, J., Maskrey, N. (2014). Evidence based medicine: a

movement in crisis? BMJ, 348, g3725.

Murray, R.M. (2017). Mistakes I Have Made in My Research Career, Schizophrenia

Bulletin,43(2), 253-256

Ioannidis, J.P. (2017). Does evidence-based hearsay determine the use of medical

treatments? Social Science & Medicine, 177, 256-258

Simpkin, A.L., & Schwartzstein, R.M. (2016). Tolerating Uncertainty — The Next

Medical Revolution? NEJM, 375(18): 1713-1715

Thomas, P., Bracken, P., Timimi, S. (2012). The Limits of Evidence-Based Medicine in

Psychiatry. Philosophy, Psychiatry, & Psychology, 19(4), 295–308

Commercial Bias in Psychiatry Literature & Practice, And What You Can Do About It

Spielmans, G. I. & Parry, P. I. (2010). From Evidence-based Medicine to

Marketing-based Medicine: Evidence from Internal Industry Documents. Journal

of Bioethical Inquiry, 7, 13-29.

Schiff, G. D., Galanter, W. L., Duhig, J., Lodolce, A. E., Koronkowski, M. J., &

Lambert, B. L. (2011). Principles of conservative prescribing. Archives of Internal

Medicine, 171, 1433-1440.

Cosgrove, L., Vannoy, S., Mintzes, B., &Shaughnessy, A.F. (2016). Under the Influence:

The Interplay among Industry, Publishing, and Drug Regulation. Accountability in

Research 23(5), 257–79

Stamatakis, E., Weiler, R., & Ioannidis, J. P. A. (2013). Undue industry influences that

distort healthcare research, strategy, expenditure and practice: a review. European

journal of clinical investigation, 43(5), 469–475

Kendall, T. (2011). The rise and fall of the atypical antipsychotics. The British journal of

psychiatry: the journal of mental science, 199(4), 266–268

Mitigating Bias in Literature Evaluation

Keller, M. B., Ryan, N. D., Strober, M., Klein, R. G., Kutcher, S. P., Birmaher, B. et

al. (2001). Efficacy of paroxetine in the treatment of adolescent major depression: a

randomized, controlled trial. J Am Acad.Child Adolesc.Psychiatry, 40, 762-772.

Jureidini, J.N., Amsterdam, J.D., McHenry, L.B. (2016). The citalopram CIT-MD-18

pediatric depression trial: Deconstruction of medical ghostwriting, data

mischaracterisation and academic malfeasance. The International Journal of Risk &

Safety in Medicine, 28(1), 33-43

= required reading = suggested reading 4

Ioannidis, J.P. (2016). Why Most Clinical Research Is Not Useful. PLoS Medicine, 13(6),

e1002049

Ghaemi, S. N. (2009). A Clinician’s Guide to Statistics and Epidemiology in Mental

Health: Measuring Truth and Uncertainty (1st ed.). Cambridge University Press

Greenhalgh, T. (2014). How to Read a Paper: The Basics of Evidence-Based Medicine

(5th ed.). BMJ Books

Moncrieff, J. & Cohen, D. (2009). How do psychiatric drugs work? BMJ, 338, b1963

Stimulants

Arnold LE, Hodgkins P, Caci H, Kahle J, Young S. Effect of treatment modality on long-

term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS One

2015; 10:e0116407.

Awudu GAH, Besag FMC. Cardiovascular effects of methylphenidate, amphetamines

and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.

Drug Saf 2014; 37:661-76.

Baweja R, Mattison RE, Waxmonsky JG. Impact of attention-deficit hyperactivity

disorder on school performance: what are the effects of medication? Pediatr Drugs 2015;

17:459-77.

Bélanger SA, Warren AE, Hamilton RM, Gray C, Gow RM, Sanatani S, et al. Cardiac

risk assessment before the use of stimulant medications in children and youth. Paediatr

Child Health 2009; 14:579-92.

Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF,

Bloch MH. Meta-analysis: risk of tics associated with psychostimulant use in

randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2015;

54:728-36.

Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al.

Practitioner review: current best practice in the management of adverse events during

treatment with ADHD medications in children and adolescents. J Child Psychol

Psychiatry 2013; 54:227-46.

Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH.

Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with

attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2015; 25:611-

7.

Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages,

disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009;

48:240-8. (Read for third seminar on Stimulants.)

Hinshaw SP, Arnold LE; For the MTA Cooperative Group. ADHD, Multimodal

Treatment, and Longitudinal Outcome: Evidence, Paradox, and Challenge. Wiley

Interdiscip Rev Cogn Sci. 2015; 6:39-52.

= required reading = suggested reading 5

Mazza M, D'Ascenzo F, Davico C, Biondi-Zoccai G, Frati G, Romagnoli E, et al. Drugs

for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden

death in children: a meta-analysis of observational studies. Int J Cardiol 2013; 168:4320-

1.

Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA

at 8 years: prospective follow-up of children treated for combined-type ADHD in a

multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48:484-500.

Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and

other psychotic symptoms associated with the use of attention-deficit/hyperactivity

disorder drugs in children. Pediatrics 2009; 123:611-6.

The MTA Cooperative Group: A 14-month randomized clinical trial of treatment

strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;

56:1073-86. (Read for first seminar on Stimulants.)

Murray DW, Arnold LE, Swanson J, Wells K, Burns K, Jensen P, et al. A clinical review

of outcomes of the multimodal treatment study of children with attention-

deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep 2008; 10:424-3.

Parker J, Wales G, Chalhoub N, Harpin V. The long-term outcomes of interventions for

the management of attention-deficit hyperactivity disorder in children and adolescents: a

systematic review of randomized controlled trials. Psychol Res Behav Manag 2013;

17;6:87-99.

Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for

attention-deficit/hyperactivity disorder. Pediatrics 2008; 122:451-3.

Pliszka SR, AACAP Work Group on Quality Issues. AACAP Practice parameter for the

assessment and treatment of children and adolescents with attention-deficit/hyperactivity

disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894-921.

Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, Vohra S.

Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and

adolescents. Cochrane Database Syst Rev 2016 Feb 4;2:CD009996.

Schwarz A. A.D.H.D. Experts re-evaluate study’s zeal for drugs. The New York Times

(December 29, 2013).

Sharpe K. Medication: the smart-pill oversell. Nature 2014; 506:146-8.

Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al.

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder

(ADHD). Cochrane Database Syst Rev 2015 Nov 25;(11):CD009885.

Swanson JM, Arnold LE, Molina BS, Sibley MH, Hechtman LT, Hinshaw SP, et al.

Young adult outcomes in the follow-up of the multimodal treatment study of

attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy,

and height suppression. J Child Psychol Psychiatry 2017, Epub ahead of print.

(Read for second seminar on Stimulants.)

Vaughan B. Kratochvil CJ. Pharmacotherapy of pediatric attention-deficit/hyperactivity

disorder. Child Adolesc Psychiatr Clin N Am 2012; 21:941-55.

= required reading = suggested reading 6

Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular

monitoring of children and adolescents with heart disease receiving medications for

attention deficit/hyperactivity disorder [corrected]: a scientific statement from the

American Heart Association Council on Cardiovascular Disease in the Young Congenital

Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation

2008; 117:2407-23.

Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity

disorder with respect to physical growth and cardiovascular function. Child Adolesc

Psychiatr Clin N Am 2008; 17:459-74.

Atomoxetine & Alpha-2 Agonists

Awudu GAH, Besag FMC. Cardiovascular effects of methylphenidate, amphetamines

and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.

Drug Saf 2014; 37:661-76.

Elbe D, Reddy D. Focus on guanfacine extended-release: a review of its use in child

and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2014; 23:48-50.

Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit

hyperactivity disorder in children and adolescents. Paediatr Drugs 2009; 11:203-26.

Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity

disorder in youth: a systematic review and meta-analysis of monotherapy and add-on

trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014; 53:153-73.

Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of

α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related

disorders. J Child Adolesc Psychopharmacology 2013; 23:308-19.

Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents

with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis

and metaregression. J Am Acad Child Adolesc Psychiatry 2014;53:174-87.

The Tourette’s Syndrome Study Group: Treatment of ADHD in children with tics: a

randomized controlled trial. Neurology 2002; 58:527-36.

Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review:

pharmacological treatment of tic disorders—efficacy of antipsychotic and alpha-2

adrenergic agonist agents. Neurosci Biobehav Rev 2013; 37:1162-71.

Antipsychotics

Abidi S, Mian I, Garcia-Ortega I, Lecomte T, Raedler T, Jackson K, Jackson K,

Pringsheim T, Addington D. Canadian Guidelines for the Pharmacological

Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children

and Youth. Can J Psychiatry. 2017 Sep;62(9):635-647.

= required reading = suggested reading 7

Pillay J, Boylan K, Carrey N, Newton A, Vandermeer B, Nuspl M, MacGregor T,

Jafri SHA, Featherstone R, Hartling L. First- and Second-Generation

Antipsychotics in Children and Young Adults: Systematic Review Update.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Mar.

Gorman DA, Gardner DM, Murphy AL, Feldman M, Bélanger SA, Steele MM, Boylan

K, Cochrane-Brink K, Goldade R, Soper PR, Ustina J, Pringsheim T.

Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in

children and adolescents with attention-deficit hyperactivity disorder, oppositional

defiant disorder, or conduct disorder. Can J Psychiatry 2015;60(2):62–76

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Atypical antipsychotics for psychosis in adolescents. Cochrane Database of Systematic

Reviews 2013, Issue 10. Art. No.: CD009582. DOI: 10.1002/14651858.CD009582.pub2.

Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of

oppositional behaviour, conduct problems, and aggression in children and adolescents

with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct

disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2

agonists, and atomoxetine. Can J Psychiatry. 2015 Feb;60(2):42-51.

Pringsheim T, Hirsch L, Gardner D, Gorman DA.

The pharmacological management of oppositional behaviour, conduct problems, and

aggression in children and adolescents with attention-deficit hyperactivity disorder,

oppositional defiant disorder, and conduct disorder: a systematic review and meta-

analysis. Part 2: antipsychotics and traditional mood stabilizers.

Can J Psychiatry. 2015 Feb;60(2):52-61.

Pringsheim T, Panagiotopoulos C, Davidson J, Ho J.

Evidence-Based Recommendations for Monitoring Safety of Second Generation

Antipsychotics in Children and Youth.

The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in

Children (CAMESA) Guideline Project. J Can Acad Child Adolesc Psychiatry 2011

August; 20(3): 218-233.

Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al.

Double-blind comparison of first- and second-generation antipsychotics in early-onset

schizophrenia and schizo-affective disorder: findings from the treatment of early-onset

schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008

Nov;165(11):1420-31.

Book Chapters:

Clinical Handbook of Psychotropic Drugs for Children and Adolescents. 3rd Ed.

Elbe, Bezchlibnyk-Butler, Virani, Procyshyn (EDS.)

Antipsychotic Chapter (p.119-202).

Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications

Stephen, Stahl Chapter 5: Antipsychotic Agents

= required reading = suggested reading 8

SSRIs

Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, et al. Switching to

another SSRI or to venlafaxine with or without cognitive behavioral therapy for

adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

JAMA2008 Feb 27;299(8):901-13.

Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA:

Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric

antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;

297(15):1683-96

Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. Selective

serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without

cognitive behaviour therapy in adolescents with major depression: randomised controlled

trial. BMJ2007 Jul 21;335(7611):142

March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M,

McNulty S, Vitiello B, Severe J: Fluoxetine, cognitive-behavioral therapy, and their

combination for adolescents with depression: Treatment for Adolescents With

Depression Study (TADS) randomized controlled trial. JAMA 2004; 292(7):807-20

(Read for first seminar on SSRIs.)

The POTS Team: Cognitive-behavior therapy, sertraline, and their combination for

children and adolescents with obsessive-compulsive disorder: the Pediatric OCD

Treatment Study (POTS) randomized controlled trial. JAMA 2004; 292(16):1969-76

Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in

juvenile depression: meta-analysis. Br J Psychiatry2008 Jul;193(1):10-7

Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, et al.

Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N

Engl J Med2008 Dec 25;359(26):2753-66. (Read for second seminar on SSRIs.)

Watson HJ, Rees CS. Meta-analysis of randomized, controlled treatment trials for

pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry2008 May;49(5):489-

98.

Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, et al.

Comparative efficacy and tolerability of antidepressants for major depressive disorder in

children and adolescents: a network meta-analysis. Lancet 2016; 388(10047):881-90.

Garland EJ, Kutcher S, Virani A, Elbe D. Update on the use of SSRIs and SNRIs with

children and adolescents in clinical practice (Position Paper). J Can Acad Child Adolesc

Psychiatry 2016; 25(1):4-10.

Ivarsson T, Skarphedinsson G, Kornør H, Axelsdottir B, Biedilæ S, Heyman I, et al. The

place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive

disorder (OCD) in children and adolescents: views based on a systematic review and

meta-analysis. Psychiatry Res 2015; 227(1):93-103.

= required reading = suggested reading 9

Varigonda AL, Jakubovski E, Taylor MJ, Freemantle N, Coughlin C, Bloch MH.

Systematic review and meta-analysis: early treatment responses of selective serotonin

reuptake inhibitors in pediatric major depressive disorder. J Am Acad Child Adolesc

Psychiatry 2015; 54(7):557-64.

Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early

treatment responses of selective serotonin reuptake inhibitors and clomipramine in

pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2016;

55(10):851-859.

Walkup JT. Antidepressant efficacy for depression in children and adolescents: industry-

and NIMH-funded studies. Am J Psychiatry 2017; 174(5):430-437.

Other “New” Antidepressants

Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, et al. Switching

to another SSRI or to venlafaxine with or without cognitive behavioral therapy for

adolescents with SSRI-resistant depression: the TORDIA randomized controlled

trial. JAMA2008 Feb 27;299(8):901-13.

Carlat D. Dr. Drug Rep. New York Times Magazine 2007:64-9.

Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y: Venlafaxine ER for the treatment of

pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad

Child Adolesc Psychiatry 2007; 46(4):479-88

March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A Randomized controlled

trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol

Psychiatry2007 Nov 15;62(10):1149-54.

Rynn MA, Riddle MA, Yeung PP, Kunz NR: Efficacy and safety of extended-release

venlafaxine in the treatment of generalized anxiety disorder in children and adolescents:

two placebo-controlled trials. Am J Psychiatry 2007; 164(2):290-300

Placebo

Bingel U; Placebo Competence Team. Avoiding nocebo effects to optimize treatment

outcome. JAMA 2014; 312:693-4.

Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. Placebo response in randomized

controlled trials of antidepressants for pediatric major depressive disorder. Am J

Psychiatry 2009; 166:42-9.

Rutherford BR, Sneed JR, Tandler JM, Rindskopf D, Peterson BS, Roose SP.

Deconstructing pediatric depression trials: an analysis of the effects of expectancy and

therapeutic contact. J Am Acad Child Adolesc Psychiatry 2011; 50:782-95.

Murray D, Stoessl AJ. Mechanisms and therapeutic implications of the placebo

effect in neurological and psychiatric conditions. Pharmacol Ther. 2013;140(3):306-

18.

= required reading = suggested reading 10

Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, et al.

Characteristics of placebo responders in pediatric clinical trials of attention-

deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2009; 48:1165-72.

Parellada M, Moreno C, Moreno M, Espliego A, de Portugal E, Arango C. Placebo effect

in child and adolescent psychiatric trials. Eur Neuropsychopharmacol 2012; 22:787-99.

Waschbusch DA, Pelham WE Jr, Waxmonsky J, Johnston C. Are there placebo effects in

the medication treatment of children with attention-deficit hyperactivity disorder? J Dev

Behav Pediatr 2009; 30:158-68.

Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label

placebo treatment in chronic low back pain: a randomized controlled trial. Pain.

2016;157(12):2766-2772

The Psychology of Psychopharmacology

Cabaniss DL: Shifting gears: The challenge to teach students to think psychodynamically

and pharmacologically at the same time. Psychoanal Inquiry 1998; 18: 639-656.

Chubinsky P, Hojman H. Psychodynamic perspectives on psychotropic medications for

children and adolescents. Child Adolesc Psychiatric Clin N Am 2013; 22:351-66.

Chubinsky P, Rappaport N. Medication and the fragile alliance: the complex meanings of

psychotropic medication to children, adolescents, and families. J Infant Child Adolesc

Psychother 2006; 5:111-23.

Floersch J, Towsend L, Longhofer J, et al. Adolescent experience of psychotropic

treatment. Transcult Psychiatry 2009; 46:157-79.

Kocsis JH, Leon AC, Markowitz JC, et al. Patient preference as a moderator of outcome

for chronic forms of major depressive disorder treated with nefazodone, cognitive

behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry

2009; 70:354-61.

Leuchter AF, Hunter AM, Tartter M, et al. Role of pill-taking, expectation and

therapeutic alliance in the placebo response in clinical trials for major depression. Br J

Psychiatry 2014;205:443-9.

Mallo CJ, Mintz DL. Teaching all the evidence bases: reintegrating psychodynamic

aspects of prescribing into psychopharmacology training. Psychodyn Psychiatry 2013;

41:13-37.

McKay KM, Imel ZE, Wampold BE. Psychiatrist effects in the psychopharmacological

treatment of depression. J Affect Disord 2006;92:287-90.

Mintz DL. Psychodynamic Trojan Horses: using psychopharmacology to teach

psychodynamics. J Am Acad Psychoanal Dyn Psychiatr 2006; 34:151-61.

Mintz DL. Teaching the prescriber's role: the psychology of psychopharmacology.

Acad Psychiatry 2005; 29:187-94.

= required reading = suggested reading 11

Mintz DL, Flynn DF. How (not what) to prescribe: nonpharmacologic aspects of

psychopharmacology. Psychiatr Clin North Am 2012; 35:143-63.

Perry S, Cooper AM, Michels R. The psychodynamic formulation: its purpose, structure,

and clinical application. Am J Psychiatry 1987; 144:543-50.

Pruett KD, Joshi SV, Martin A. Thinking about prescribing: the psychology of

psychopharmacology. In: Martin A, Scahill L, Kratochvil C eds. Pediatric

Psychopharmacology: Principles and Practice. 2nd ed. New York, NY: Oxford University

Press; 2011:422-33.

Rappoport N, Chubinsky P. The meaning of psychotropic medications for children,

adolescents, and their families. J Am Acad Child Adolesc Psychiatry 2000; 39:1198-

1200.

Rutherford BR, Wall MM, Brown PJ, Choo TH, Wager TD, Peterson BS, et al. Patient

expectancy as a mediator of placebo effects in antidepressant clinical trials. Am J

Psychiatry 2017; 174:135-42.

Lithium

Barzman DH, Findling RL. Pharmacological treatment of pathologic aggression in

children. Int Rev Psychiatry2008 Apr;20(2):151-7

Blader JC. Another Look at the Treatment of Early-Age Mania (TEAM) Trial. Comment

in J Am Acad Child Adolesc Psychiatry 2013 February:52(2): 205-206

Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in

pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J

Am Acad Child Adolesc Psychiatry 2007; 46(6):687-700

Correll CU, Sheridan EM, DelBello MP: Antipsychotic and mood stabilizer efficacy and

tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of

acute, randomized, placebo-controlled trials, Bipolar Disord 2010; 12: 116-141.

Findling RL, Robb A, McNamara NK, Pavuluri M, Kafantaris V, Scheffer R et al.

Lithium in the Acute Treatment of Bipolar I Disorder: A Double-Blind, Placebo-

Controlled Study. Pediatrics 2015; 136(5): 885894.

Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, Heath J: Double-blind

and placebo-controlled study of lithium for adolescent bipolar disorders with secondary

substance dependency. J Am Acad Child Adolesc Psychiatry 1998; 37(2):171-8.

Geller B, Luby J, Joshi P, Wagner K, Emslie G, Walkup J et al. A Randomized

Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of

Bipolar I Disorder, Manic or Mixed Phase, in Children and Adolescents. Arch Gen

Psychiatry 2012;69(5):515-528.

Gorman DA, Gardner GM, Murphy AL, Feldman M, Belanger SA, Steele MM et al.

Canadian Guidelines on Pharmacotherapy for Disruptive and Aggressive Behaviour in

Children and Adolescents With Attention-Deficit Hyperactivity Disorder, Oppositional

Defiant Disorder, or Condcut Disorder. 2015; 60(2)62-76.

= required reading = suggested reading 12

Hall RC, Perl M, Pfefferbaum, B. Lithium Therapy and Toxicity. Am Fam Physician

1979 April 19(4):133-139.

Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M: Treatment

guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc

Psychiatry 2005; 44(3):213-35.

Landersdorfer CB, Findling LF, Frazier JA, Kafantaris V, Kirkpatrick CMJ. Lithium in

Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens

via Population Pharmacokinetics/Pharmacodynamics. Clin Pharmacokinet 2017; 56:77-

90.

Liu HY, Potter MP, Woodworth KY, Yorks DM, Petty CR, Wozniak JR et al.

Pharmacologic Treatments for Pediatric Bipolar Disorder: A Review and Meta-

Analysis. J Am Acad Child Adolesc Psychiatry 2011 August;50(8);749-762.e39.

McClellan J, Commentary: Treatment Guidelines for Child and Adolescent Bipolar

Disorder. J Am Acad Child Adolesc Psychiatry 2005; 44(3):236-39.

Washburn JJ, West AE, Heil JA. Treatment of Pediatric Bipolar Disorder: A

Review. Minerva Psichiatr 2011 March; 52(1): 21-35.

Anticonvulsants

Azorin JM, Findling RL. Valproate use in children and adolescents with bipolar disorder.

CNS Drugs2007;21(12):1019-33.

Biederman J, Joshi G. Mick E, Doyle R, Georgiopouls A, Hammerness P, Kotarski M,

Williams C, Wozniak j. A prospective open-label trail of lamotrigine monotherapy in

children and adolescents with bipolar disorder. CNS Neuroscience & Therapeutics 2010;

16:91-102

Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or

monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child

Adolesc Psychiatry2006 Mar;45(3):298-304Correll CU, Sheridan EM, DelBello MP:

Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients

with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled

trials, Bipolar Disord 2010; 12: 116-141.

Correll CU: Weight gain and metabolic effects of mood stabilizers and antipsychotics in

pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J

Am Acad Child Adolesc Psychiatry 2007; 46(6):687-700.

Findling RL, Chang K, Robb A, Foster VJ, Horrigan J, Krishen A et al. Adjunctive

Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled,

Randomized Withdrawal Study. J Am Acad Child Adolesc Psychiatry. 2015;

54(12):1020-1031.e3.

Geller B, Luby J, Joshi P, Wagner K, Emslie G, Walkup J et al. A Randomized

Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of

= required reading = suggested reading 13

Bipolar I Disorder, Manic or Mixed Phase, in Children and Adolescents. Arch Gen

Psychiatry 2012;69(5):515-528.

Gorman DA, Gardner GM, Murphy AL, Feldman M, Belanger SA, Steele MM et al.

Canadian Guidelines on Pharmacotherapy for Disruptive and Aggressive Behaviour in

Children and Adolescents With Attention-Deficit Hyperactivity Disorder, Oppositional

Defiant Disorder, or Condcut Disorder. 2015; 60(2)62-76.

Haddad PM, Das A, Ashfaq M, Wieck A. A review of valproate in psychiatric practice.

Expert opin Drug Metab Toxicol 2009; 5(5): 539-551

Hamrin V, DeSanto Iennaco, J. Psychopharmacology of pediatric bipolar disorder. Expert

Rev Neurother 2010; 10(7), 1053-1088

Joshi G, Wozniak J, Mick E, Doyle R, Hammerness P, Geogiopolous A, Kotarski M,

Aleardi M, Williams C, Walls S, Biederman J. A prospective open label trial of extended-

release carbamazepine monotherapy in children with bipolar disorder. J of Child and

Adolesc Psychopharm 2010; 20(1):7-14

Leon AC, Solomon DA, Li C, Fiedorowicz JG, Coryell WH, Endicott J, Keller MB.

Antiepileptic Drugs for Bipolar Disorder and the Risk of Suicidal Behavior: A 30-Year

Observational Study Am J Psychiatry 2012 March169(3):285-291

Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP et al.

Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis

in children: a pooled analysis. Pediatrics 2009 Feb;123(2):e297-304

Liu HY, Potter MP, Woodworth KY, Yorks DM, Petty CR, Wozniak JR et al.

Pharmacologic Treatments for Pediatric Bipolar Disorder: A Review and Meta-

Analysis. J Am Acad Child Adolesc Psychiatry 2011 August;50(8);749-762.e39

Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, et al. A

double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of

bipolar disorder in children and adolescents. Am J Psychiatry2006 Jul;163(7):1179-86.

Wagner KD, Redden L, Kowatch RA, Wilens TE, Segal S, Chang K, Wozniak P, Vigna

NV, Abi-Saab W, Saltarelli M. A double-blind, placebo-controlled trial of divalproex

extended-release in the treatment of bipolar disorder in children and adolescents. J Am

Acad Child Adolesc Psychiatry 2009; 48(5):519-532

Washburn JJ, West AE, Heil JA. Treatment of Pediatric Bipolar Disorder: A

Review. Minerva Psichiatr 2011 March; 52(1): 21-35

Psychopharmacology in Autism Spectrum Disorders

Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, et al.;

Research Units on Pediatric Psychopharmacology Autism Network. Medication and

parent training in children with pervasive developmental disorders and serious

behavior problems: results from a randomized clinical trial. J Am Acad Child

Adolesc Psychiatry 2009; 48:1143-54.

= required reading = suggested reading 14

Carrasco M, Volkmar FR, Bloch MH. Pharmacologic treatment of repetitive behaviors in

autism spectrum disorders: evidence of publication bias. Pediatrics 2012; 129:e1301-10.

Elbe D, Lalani Z. Review of the pharmacotherapy of irritability of autism. J Can Acad

Child Adolesc Psychiatry 2012; 21:130-46.

Ghanizadeh A. Atomoxetine for treating ADHD symptoms in autism: a systematic

review. J Atten Disord 2013; 17:635-40.

Handen BL, Taylor J, Tumuluru R. Psychopharmacological treatment of ADHD

symptoms in children with autism spectrum disorder. Int J Adolesc Med Health 2011;

23:167-73.

Smith T, Aman MG, Arnold LE, Silverman LB, Lecavalier L, Hollway J, Tumuluru

R, Hyman SL, Buchan-Page KA, Hellings J, Rice RR Jr, Brown NV, Pan X, Handen BL.

Atomoxetine and Parent Training for Children With Autism and

Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study. J Am Acad

Child Adolesc Psychiatry. 2016 Oct;55(10):868-876.e2. doi:

10.1016/j.jaac.2016.06.015. Epub 2016 Aug 2. PubMed PMID: 27663942; PubMed

Central PMCID: PMC5108566.

Handen BL, Aman MG, Arnold LE, Hyman SL, Tumuluru RV, Lecavalier L,

Corbett-Dick P, Pan X, Hollway JA, Buchan-Page KA, Silverman LB, Brown NV, Rice

RR Jr, Hellings J, Mruzek DW, McAuliffe-Bellin S, Hurt EA, Ryan MM, Levato L,

Smith T. Atomoxetine, Parent Training, and Their Combination in Children With

Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. J Am Acad

Child Adolesc Psychiatry. 2015 Nov;54(11):905-15. doi: 10.1016/j.jaac.2015.08.013.

Epub 2015 Sep 3. PubMed PMID: 26506581; PubMed

Central PMCID: PMC4625086.

Tumuluru RV, Corbett-Dick P, Aman MG, Smith T, Arnold LE, Pan X, Buchan-Page

KA, Brown NV, Ryan MM, Hyman SL, Hellings J, Williams C, Hollway JA, Lecavalier

L, Rice RR Jr, McAuliffe-Bellin S, Handen BL. Adverse Events of Atomoxetine in a

Double-Blind Placebo-Controlled Study in Children with Autism. J Child Adolesc

Psychopharmacol. 2017 May 16. doi: 10.1089/cap.2016.0187. [Epub ahead of print]

PubMed PMID: 28509573.

King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al.; STAART

Psychopharmacology Network. Lack of efficacy of citalopram in children with autism

spectrum disorders and high levels of repetitive behavior: citalopram ineffective in

children with autism. Arch Gen Psychiatry 2009; 66:583-90.

Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-

controlled, fixed-dose study of aripiprazole in children and adolescents with irritability

associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48:1110-9.

McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al.; Research

Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with

autism and serious behavioral problems. N Engl J Med 2002; 347:314-21.

= required reading = suggested reading 15

Research Units on Pediatric Psychopharmacology Autism Network. Randomized,

controlled, crossover trial of methylphenidate in pervasive developmental disorders with

hyperactivity. Arch Gen Psychiatry 2005; 62:1266-74.

Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors

(SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2010; Issue

8. Art. No.: CD004677.

Young NJ, Findling RL. An update on pharmacotherapy for autism spectrum disorder in

children and adolescents. Curr Opin Psychiatry 2015; 28:91-101.

Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R,

Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle

J; Research Units on Pediatric Psychopharmacology Autism Network.

Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum

Disorder. Am J Psychiatry. 2015 Dec;172(12):1197-206. doi:

10.1176/appi.ajp.2015.15010055. Epub 2015 Aug 28. PubMed PMID: 26315981.

Psychopharmacology for Sleep and Agitation

Gruber R, Carrey N, Weiss SK, Frappier JY, Rourke L, Brouillette RT, Wise MS.

Position statement on pediatric sleep for psychiatrists. J Can Acad Child Adolesc

Psychiatry 2014; 23:174-95.

Van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB.

Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset

insomnia. J Am Acad Child Adolesc Psychiatry 2007; 46:233-41.

Owens JA. Pharmacotherapy of pediatric insomnia. J Am Acad Child Adolesc Psychiatry

2009; 48:99-107.

Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. Eszopiclone for insomnia

associated with attention-deficit/hyperactivity disorder. Pediatrics 2014; 134:e1095-103.

Pelayo R1, Yuen K. Pediatric sleep pharmacology. Child Adolesc Psychiatr Clin N Am

2012; 21:861-83.

Maski K, Owens JA. Insomnia, parasomnias, and narcolepsy in children: clinical

features, diagnosis, and management. Lancet Neurol 2016; 15:1170-81.

Carubia B, Becker A, Levine BH. Child Psychiatric Emergencies: Updates on

Trends, Clinical Care, and Practice Challenges. Curr Psychiatry Rep 2016; 18:41

Hilt RJ, Woodward TA. Agitation treatment for pediatric emergency patients. J Am Acad

Child Adolesc Psychiatry 2008; 47:132-8.

Allison L, Moncrieff J. 'Rapid tranquillisation': an historical perspective on its emergence

in the context of the development of antipsychotic medications. Hist Psychiatry 2014;

25:57-69.

= required reading = suggested reading 16

Gorman DA, Gardner DM, Murphy AL, Feldman M, Bélanger SA, Steele MM, Boylan

K, Cochrane-Brink K, Goldade R, Soper PR, Ustina J, Pringsheim T. Canadian

guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and

adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or

conduct disorder. Can J Psychiatry 2015; 60:62-76.

Turkel SB, Hanft A. The pharmacologic management of delirium in children and

adolescents. Paediatr Drugs 2014; 16:267-74.

Fung LK, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, Coury D, Whitaker A,

Veenstra-Vanderweele J, Hardan AY. Pharmacologic Treatment of Severe Irritability and

Problem Behaviors in Autism: A Systematic Review and Meta-analysis. Pediatrics. 2016;

137:S124-35.

Benarous X, Consoli A, Guilé JM, Garny de La Rivière S, Cohen D, Olliac B. Evidence-

based treatments for youths with severely dysregulated mood: a qualitative systematic

review of trials for SMD and DMDD. Eur Child Adolesc Psychiatry 2017; 26:5-23.

Gurnani T, Ivanov I, Newcorn JH. Pharmacotherapy of Aggression in Child and

Adolescent Psychiatric Disorders. J Child Adolesc Psychopharmacol 2016; 26:65-73.

Cummings MR, Miller BD. Pharmacologic management of behavioral instability in

medically ill pediatric patients. Curr Opin Pediatr 2004; 16:516-22.

Scotto Rosato N, Correll CU, Pappadopulos E, Chait A, Crystal S, Jensen PS; Treatment

of Maladaptive Aggressive in Youth Steering Committee. Treatment of maladaptive

aggression in youth: CERT guidelines II. Treatments and ongoing management.

Pediatrics 2012; 129:e1577-86.

Pappadopulos E, Rosato NS, Correll CU, Findling RL, Lucas J, Crystal S, Jensen PS.

Experts' recommendations for treating maladaptive aggression in youth. J Child Adolesc

Psychopharmacol 2011; 21:505-15.

Appendix

Delbello MP, Findling RL, Kushner S, Wang D, Olson WH, Capece JA, et al. A pilot

controlled trial of topiramate for mania in children and adolescents with bipolar disorder.

J Am Acad Child Adolesc Psychiatry 2005; 44:539-47.

Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic

antidepressant use in children and adolescents. J Am Acad Child Adolesc

Psychiatry1999; 38:513-6.

Grady MM, Stahl SM. Practical guide for prescribing MAOIs: debunking myths and

removing barriers. CNS Spectr 2012; 17:2-10.

Mancuso CE, Tanzi MG, Gabay M: Paradoxical reactions to benzodiazepines: literature

review and treatment options. Pharmacotherapy 2004; 24:1177-85.

Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention

deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database

Syst Rev 2014, Issue 9.

= required reading = suggested reading 17

Witek MW, Rojas V, Alonso C, Minami H, Silva RR: Review of benzodiazepine use in

children and adolescents. Psychiatr Q 2005; 76:283-96.

Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Modafinil for the

treatment of attention-deficit/hyperactivity disorder: a meta-analysis. J Psychiatr Res

2017; 84:292-300.